AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Preclinical Data Indicate Candidate Vaccine's Ability To Inhibit Viral Mutation.(Brief Article)
2001 APR 18 - (NewsRx.com & NewsRx.net) --
Epimmune, Inc. (EPMN) announced on April 2, 2001, positive pre-clinical data on its HIV vaccine, which is designed to directly address the problem of viral mutation.
Company scientists reported that the vaccine stimulated multiple anti-HIV cytotoxic T-cell immune responses in animal models.
Epimmune has begun manufacturing the vaccine for human testing and plans to initiate clinical trials late this year or early 2002 in both non-infected volunteers and in individuals infected with HIV.
Strong cellular immunity is characteristic of long-term non-progressors or HIV positive individuals who do not progress to AIDS for long periods even without antiretroviral drug therapy. Epimmune's approach to vaccine development is based on epitopes from non-mutating regions of multiple virus proteins that are specifically selected for their ability to stimulate two types of cellular immunity, cytotoxic T cells (CTLs) and helper T cells (HTLs). Together, CTLs and HTLs comprise the body's natural defense against HIV in which CTLs are capable of directly destroying virus-infected cells but require HTLs, which produce immune-boosting ...
- Epimmune Grants License For Ex Vivo Applications Of Cancer Epitopes.
- Newspaper article from: Vaccine Weekly October 24, 2001 700+ words
...amp; NewsRx.net) -- Epimmune Inc. has granted Anosys Inc...and nonpatented rights to Epimmune's universal breast, colon...with tumor antigens such as Epimmune's BCL or prostate epitopes...This article was prepared by Vaccine Weekly editors from staff and other...
- Epimmune and Genencor Achieve Preclinical Milestone.(Brief Article)
- Newspaper article from: Vaccine Weekly February 6, 2002 700+ words
...announced the collaboration with Epimmune we indicated a target of 18...research and development at Epimmune, added that the selection...relationship between Genencor and Epimmune and underscores the commitment...This article was prepared by Vaccine Weekly editors from staff and other...
- Epimmune, Bavarian Combine Technologies To Develop HIV Vaccine.(Brief Article)
- Newspaper article from: Vaccine Weekly December 19, 2001 700+ words
...pleased to be working with Epimmune in the area of HIV...that by working with Epimmune we will strengthen our...effective HIV vaccine. Epimmune is the recognized leader...article was prepared by Vaccine Weekly editors from staff and...
- Epimmune Provides HIV Vaccine Program Update.(Brief Article)
- Newspaper article from: Vaccine Weekly October 10, 2001 700+ words
...months after trial initiation. Epimmune's initial HIV vaccine candidate...regions of the HIV virus using Epimmune proprietary processes. This...vaccine candidate will include Epimmune's PADRE universal helper...This article was prepared by Vaccine Weekly editors from staff and other...
- Epimmune receives FDA clearance to initiate phase I/II therapeutic vaccine...
- Newspaper article from: Vaccine Weekly July 17, 2002 700+ words
...amp; NewsRx.net) -- Epimmune, Inc., (EPMN), a biotechnology...immune system. The goal of Epimmune's EP HIV-1090 therapeutic...MD, president and CEO of Epimmune. "DNA vaccines appear to...This article was prepared by Vaccine Weekly editors from staff and other...
- Epimmune earns milestone payment under cancer epitope license.
- Newspaper article from: Vaccine Weekly October 8, 2003 700+ words
...covered by the agreement, Epimmune will be entitled to an additional...disclosed. In August 2001, Epimmune granted Anosys a nonexclusive...president, cancer programs at Epimmune, said, "Achievement of...This article was prepared by Vaccine Weekly editors from staff and other...
- Epimmune provides HIV vaccine program update.(Brief Article)
- Newspaper article from: Vaccine Weekly March 6, 2002 700+ words
...potent T-cell responses." Epimmune's initial HIV vaccine candidate...conserved regions of the HIV using Epimmune proprietary processes. This...vaccine candidate will include Epimmune's PADRE universal helper...This article was prepared by Vaccine Weekly editors from staff and other...
- Epimmune, Bavarian Nordic Combine Technologies To Develop HIV Vaccine.(Brief...
- Newspaper article from: Vaccine Weekly December 26, 2001 700+ words
...and chief executive officer of Epimmune. Epimmune has evaluated a number of viral...an effective HIV vaccine. "Epimmune is the recognized leader in...This article was prepared by Vaccine Weekly editors from staff and other...